CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Apellis Pharmaceuticals
Company Type: Therapeutic development
Main focus: Developing novel therapeutics through targeting of complement protein C3
Company stage: Clinical (pre-clinical for gene editing)
Diseases: Liver, retinal, and neurological diseases
Genome-editing tool: Base editing
Funding stage: Post-IPO Debt
Location: Waltham, Massachusetts, USA
Website: https://apellis.com/
Pipeline: https://apellis.com/our-science/our-pipeline/
Partners: Beam Therapeutics
Apellis Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases. The company focuses on inhibiting the complement system via complement protein C3 targeting. Apellis’ broad portfolio includes approved non-gene-editing therapies for the rare disease paroxysmal nocturnal hemoglobinuria and the eye disease geographic atrophy. Apellis recently entered an exclusive collaboration with Beam Therapeutics to develop an undisclosed gene-editing programme.
